Exercise Intervention for Health Research Group (EXINH-RG), Department of Physiotherapy, Universitat de València, Valencia 46010, Spain.
Navarrabiomed, Navarra Hospital Complex (CHN), Public University of Navarra (UPNA), Navarra Medical Research Institute (IdiSNA), Pamplona 31008, Spain; CIBER of Frailty and Healthy Aging (CIBERFES), Instituto de Salud Carlos III, Madrid 28029, Spain.
J Sport Health Sci. 2021 Dec;10(6):609-619. doi: 10.1016/j.jshs.2021.06.004. Epub 2021 Jun 29.
Cardiorespiratory fitness (CRF) is inversely associated with mortality in apparently healthy subjects and in some clinical populations, but evidence for the association between CRF and all-cause and/or cardiovascular disease (CVD) mortality in patients with established CVD is lacking. This study aimed to quantify this association.
We searched for prospective cohort studies that measured CRF with cardiopulmonary exercise testing in patients with CVD and that examined all-cause and CVD mortality with at least 6 months of follow-up. Pooled hazard ratios (HRs) were calculated using random-effect inverse-variance analyses.
Data were obtained from 21 studies and included 159,352 patients diagnosed with CVD (38.1% female). Pooled HRs for all-cause and CVD mortality comparing the highest vs. lowest category of CRF were 0.42 (95% confidence interval (95%CI): 0.28-0.61) and 0.27 (95%CI: 0.16-0.48), respectively. Pooled HRs per 1 metabolic equivalent (1-MET) increment were significant for all-cause mortality (HR = 0.81; 95%CI: 0.74-0.88) but not for CVD mortality (HR = 0.75; 95%CI: 0.48-1.18). Coronary artery disease patients with high CRF had a lower risk of all-cause mortality (HR = 0.32; 95%CI: 0.26-0.41) than did their unfit counterparts. Each 1-MET increase was associated with lower all-cause mortality risk among coronary artery disease patients (HR = 0.83; 95%CI: 0.76-0.91) but not lower among those with heart failure (HR = 0.69; 95%CI: 0.36-1.32).
A better CRF was associated with lower risk of all-cause mortality and CVD. This study supports the use of CRF as a powerful predictor of mortality in this population.
心肺适能(CRF)与健康人群和某些临床人群的死亡率呈负相关,但在已确诊心血管疾病(CVD)的患者中,CRF 与全因和/或心血管疾病(CVD)死亡率之间的关联证据不足。本研究旨在量化这种关联。
我们搜索了使用心肺运动试验测量 CVD 患者 CRF 并进行了至少 6 个月随访以检查全因和 CVD 死亡率的前瞻性队列研究。使用随机效应逆方差分析计算合并危险比(HR)。
共获得 21 项研究的数据,纳入 159352 名诊断为 CVD(38.1%为女性)的患者。比较 CRF 最高与最低类别时的全因和 CVD 死亡率的合并 HR 分别为 0.42(95%置信区间[95%CI]:0.28-0.61)和 0.27(95%CI:0.16-0.48)。每增加 1 个代谢当量(1-MET)的合并 HR 与全因死亡率显著相关(HR=0.81;95%CI:0.74-0.88),但与 CVD 死亡率无关(HR=0.75;95%CI:0.48-1.18)。CRF 高的冠状动脉疾病患者的全因死亡率风险较低(HR=0.32;95%CI:0.26-0.41),而与之相比,功能不强者的全因死亡率风险较高。每增加 1-MET 与冠状动脉疾病患者的全因死亡率风险降低相关(HR=0.83;95%CI:0.76-0.91),但与心力衰竭患者无关(HR=0.69;95%CI:0.36-1.32)。
更好的 CRF 与全因死亡率和 CVD 风险降低相关。本研究支持在该人群中使用 CRF 作为强有力的死亡率预测指标。